Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership384,205 shares
Latest Disclosed Value $ 127,071,024
Dimensional Fund Advisors Lp reports 27.28% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 384,205 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $109,767,368 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 301,865 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 27.28% during the quarter. The current value of the position is $100,085,402 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 384,205 82,340 27.28 127,071 5.86 0.0264
2026-02-12 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 301,865 59,931 24.77 120,033 8.84 0.0252
2025-11-12 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 241,934 -63,629 -20.82 110,284 10.69 0.0237
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 305,563 -4,256 -1.37 99,633 19.11 0.0231
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 309,819 -23,842 -7.15 83,645 6.53 0.0208
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 333,661 32,272 10.71 78,520 -5.27 0.0189
2024-11-07 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 301,389 35,183 13.22 82,885 28.10 0.0201
2024-08-09 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 266,206 11,027 4.32 64,702 69.66 0.0169
2024-05-10 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 255,179 -11,855 -4.44 38,137 -25.41 0.0103
2024-02-07 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 267,034 15,123 6.00 51,126 14.60 0.0149
2023-11-09 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 251,911 10,921 4.53 44,611 -2.54 0.0146
2023-08-09 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 240,990 22,511 10.30 45,775 4.60 0.0146
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 218,479 23,903 12.28 43,762 95,032.61 0.0147
2023-02-09 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 194,576 18,310 10.39 46 -99.87 0.0137
2022-11-10 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 176,266 2,841 1.64 35,290 39.53 0.0135
2022-08-12 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 173,425 -7,846 -4.33 25,292 -14.56 0.0091
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 181,271 2,111 1.18 29,601 -2.57 0.0091
2022-02-09 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 179,160 -8,103 -4.33 30,383 -14.05 0.0092
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 187,263 -17,736 -8.65 35,351 1.74 0.0114
2021-08-12 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 204,999 -22,703 -9.97 34,747 8.07 0.0110
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 227,702 -7,299 -3.11 32,152 5.26 0.0106
2021-03-08 2020-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 235,001 -3,020 -1.27 30,545 -11.86 0.0110
2021-02-11 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 235,001 -3,020 30,545 11,031.2304
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 238,021 -8,309 -3.37 34,654 -5.01 0.0147
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 246,330 -19,428 -7.31 36,483 26.13 0.0160
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 265,758 4,513 1.73 28,926 -3.86 0.0151
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 261,245 2,278 0.88 30,087 44.45 0.0110
2019-11-12 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 258,967 7,709 3.07 20,828 14.26 0.0081
2019-08-13 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 251,258 26,788 11.93 18,229 -13.08 0.0071
2019-08-12 2019-03-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 224,470 -678 -0.30 20,972 27.78 0.0084
2019-05-10 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 224,470 -678 20,972
2019-02-26 2018-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 225,148 66,253 41.70 16,412 17.99 0.0074
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 225,148 66,253 16,412
2018-11-13 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 158,895 -3,047 -1.88 13,910 -12.78 0.0053
2018-08-10 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 161,942 -5,130 -3.07 15,948 -19.85 0.0064
2018-05-11 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 167,072 -6,685 -3.85 19,898 -9.89 0.0083
2018-02-12 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 173,757 -6,301 -3.50 22,081 4.37 0.0092
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 180,058 629 0.35 21,156 47.83 0.0092
2017-08-11 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 179,429 66,651 59.10 14,311 147.60 0.0066
2017-05-12 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 112,778 1,428 1.28 5,780 38.61 0.0028
2017-02-09 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 111,350 695 0.63 4,170 -44.42 0.0021
2016-11-10 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 110,655 9,086 8.95 7,503 33.13 0.0041
2016-08-09 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 101,569 -861 -0.84 5,636 -12.29 0.0032
2016-05-13 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 102,430 2,852 2.86 6,426 -31.46 0.0038
2016-02-10 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 99,578 -21,738 -17.92 9,375 -3.82 0.0058
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 121,316 -5,929 -4.66 9,747 -36.07 0.0064
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 127,245 2,042 1.63 15,247 16.60 0.0093
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 125,203 1,839 1.49 13,076 9.27 0.0083
2015-02-06 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 123,364 -28 -0.02 11,967 24.16 0.0079
2014-11-13 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 123,392 -7,591 -5.80 9,638 16.50 0.0068
2014-08-08 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 130,983 -91,339 -41.08 8,273 -44.57 0.0058
2014-05-14 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 222,322 871 0.39 14,925 4.77 0.0112
2014-02-12 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 221,451 -5,702 -2.51 14,246 -2.02 0.0111
2013-11-13 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 227,153 49,479 27.85 14,539 163.87 0.0126
2013-08-15 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 177,674 177,674 5,510 0.0052
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.